Showing results (231-240 of 424) with videos related to
Sort By:
Pageof 43
Cancer|April 17, 2008
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 studyAmani Asnacios, Laetitia Fartoux, Olivier Romano, et al.Hepatology (Baltimore, Md.)|December 17, 2008
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapyPatrick Ingiliz, Marc-Antoine Valantin, Claudine Duvivier, et al.The Lancet. Gastroenterology & Hepatology|March 19, 2023
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialRohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, et al.Hepatology (Baltimore, Md.)|May 25, 2013
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitisBart Staels, Anne Rubenstrunk, Benoit Noel, et al.The Journal of Clinical Investigation|May 2, 2012
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humansFadila Benhamed, Pierre-Damien Denechaud, Maud Lemoine, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 8, 2020
Real-World Burden of Nonalcoholic SteatohepatitisAndreas Geier, Mary E Rinella, Maria-Magdalena Balp, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 19, 2018
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysisMa Ai Thanda Han, Osama Altayar, Shadi Hamdeh, et al.Journal of Hepatology|February 22, 2023
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)Stephen A Harrison, Carole Thang, Sébastien Bolze, et al.Clinical Chemistry and Laboratory Medicine|April 15, 2004
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donorsFrançoise Imbert-Bismut, Djamila Messous, Vincent Thibault, et al.Journal of Hepatology|November 14, 2007
Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalitiesGeorgia Malamut, Marianne Ziol, Felipe Suarez, et al.Pageof 43